Gland Pharma Q2 FY27 Performance Review

Net Sales reached Rs 1,834 Cr, while Net Profit stood at Rs 291 Cr.

Reader Takeaway: Revenue growth and CDMO expansion remain core long-term drivers despite short-term earnings misses and regulatory watch points.

What just happened

Gland Pharma reported Q2 FY27 financial results that fell short of broker expectations. The company posted net sales of Rs 1,834 Cr and an adjusted net profit of Rs 291 Cr, marking a variance of -10.1% against estimated profit targets. EBITDA margins settled at 26.4%, slightly below the projected performance thresholds.

Why this matters

The results reflect headwinds from the Cenexi segment, which reported an EBITDA loss of €6 Mn due to planned summer shutdowns. However, the company maintains a 15% constant currency revenue growth guidance for FY27, backed by strong CDMO growth of 31% YoY and steady expansion in the Critical Injectables business.

The backstory

The board has officially approved a significant Rs 1,000 Cr investment for a brownfield expansion at the Pashamylaram facility. This project will add three isolator vial lines, with full operations targeted for FY30. Additionally, the company is scaling its portfolio through a new in-licensing term sheet for a patent-protected injectable asset from China.

Leadership Change

A critical transition is underway, with Deepak Sapra scheduled to take the helm as CEO on November 16, 2026. Markets will be monitoring his strategy regarding the total 4-year planned Capex of approximately Rs 5,000 Cr.

Risks to watch

Investors should monitor ongoing regulatory risks, including potential USFDA inspections that could result in OAI status or warning letters. Pricing pressure from new market entrants and potential delays in the biosimilars pipeline remain key risks to the current growth trajectory.

What to track next

Watch for the recovery of the Cenexi segment in Q3 and progress on the four new US product launches, including the much-anticipated Sugammadex injection.